NCT01493050View on ClinicalTrials.gov

The Effects of Sevelamer Carbonate on Diabetic Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Diabetic Nephropathy
Interventions
DRUG

Sevelamer Carbonate

1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks

DRUG

calcium carbonate

1200 mg of calcium carbonate TID with meals for 26 weeks

Trial Locations (2)

10003

Beth Israel Medical Center, New York

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Lead Sponsor

Gary Striker
All Listed Sponsors
lead

Gary Striker

OTHER

NCT01493050 - The Effects of Sevelamer Carbonate on Diabetic Nephropathy | Biotech Hunter | Biotech Hunter